AI Article Synopsis
- In 2019, the Korean Diabetes Association updated its 6th Clinical Practice Guidelines to improve management of type 2 diabetes mellitus (T2DM).
- The new guidelines emphasize the importance of controlling glycemic levels, blood pressure, and lipids, particularly in the growing obese and overweight population in Korea.
- The updated recommendations include evidence-based strategies for weight-loss therapy and the effects of specific diabetes medications on cardiovascular outcomes.
Article Abstract
The Committee of Clinical Practice Guidelines of the Korean Diabetes Association revised and updated the 6th Clinical Practice Guidelines in 2019. Targets of glycemic, blood pressure, and lipid control in type 2 diabetes mellitus (T2DM) were updated. The obese and overweight population is increasing steadily in Korea, and half of the Koreans with diabetes are obese. Evidence-based recommendations for weight-loss therapy for obesity management as treatment for hyperglycemia in T2DM were provided. In addition, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712226 | PMC |
| http://dx.doi.org/10.4093/dmj.2019.0137 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!